31 Mar 2025 | News
Twenty years ago, Technophage started as a small startup at the Institute of Molecular Medicine, with a small adventurous team isolating bacteriophages in a lab. Today, we are an international, clinical-stage biopharma with three technological platforms, driving...
3 Jan 2025 | News
Technophage is excited to kick off the new year by sharing our latest publication in Med by Cell Press. Our Phase I/IIa study results for TP-102, an innovative bacteriophage cocktail targeting infected diabetic foot ulcers, demonstrated promising outcomes and are...
28 Nov 2024 | News
Technophage congratulates INFARMED, I.P. on the approval of phage therapy in Portugal, a groundbreaking achievement celebrated alongside the release of the “Guiding Standard on the Use of Compounded Medications for Phage Therapy in the Hospital Context – Magistral...
6 Nov 2024 | News
We are thrilled to announce that Technophage has once again been recognized by IAPMEI, I.P. – Agência para a Competitividade e Inovação (Agency for Competitiveness and Innovation) with the prestigious ‘PME Líder’ distinction for 2024! Receiving this honor for another...
22 Jul 2024 | News
Technophage has been featured in the recent article “The 7 Biotech Companies in Portugal You Should Know About in 2024” by Labiotech! This recognition is a validation to our team’s hard work, dedication, and innovative spirit in advancing...
5 Jul 2024 | News
We are thrilled to announce that Technophage was selected by Innovate UK as one of the 19 most promising solutions globally in the fight against antibiotic resistance! Technophae’s CEO and CSO participated in the Inward AMR Innovation Mission UK 2024, that took...
